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Abstract The paper presents diagnostic and therapeutic
difﬁculties in two adolescents with widespread rhabdo-
myosarcoma (RMS) presenting with severe haemorrhages
resulting from disseminated intravascular coagulation
(DIC) and with laboratory features of acute tumour lysis
syndrome (ATLS). Other published cases of childhood
RMS with DIC at admission have been listed and reviewed.
It has been concluded that the clinical picture of a wide-
spread RMS in children may resemble acute hematologic
malignancy and pose a big diagnostic problem. That is why
the presence of small blue round cells morphologically
similar to lymphoblasts and/or myeloblasts in bone marrow
(BM), lacking hematopoietic makers, should prompt the
pathologist to consider possible diagnosis of RMS. Inclu-
sion of desmin, MyoD1 and myogenin Myf4 to the immu-
nohistochemical panel is obligatory in such cases. When the
representative histopathological tumour specimens are
difﬁcult to obtain, the ﬂow cytometric immunophenotyping
of BM metastases could help the standard morphological/
immunohistological diagnostic procedures and advance the
diagnosis. Recently, the ﬂow cytometric CD45- CD56?
immunophenotype together with Myf4 transcript has been
assigned to RMS cells inﬁltrating BM. In children with
disseminated RMS complicated with DIC rapid polyche-
motherapy aimed at diminishing the malignancy-triggered
procoagulant activity should be initiated. However, in cases
with concomitant ATLS the initial doses of chemotherapy
should be reduced and the metabolic disorders and renal
function monitored. The prognosis in children with RMS
metastatic to BM with signs of DIC or ATLS at admission
depends on the response to chemotherapy, however gener-
ally it is highly disappointing.
Keywords Acute tumour lysis syndrome 
Bone marrow metastasis  CD45- CD56? immunoproﬁle 
Childhood rhabdomyosarcoma  Disseminated
intravascular coagulation  Flow cytometry  Review
Introduction
Disseminated intravascular coagulation (DIC), also known
as consumption coagulopathy, is an abnormal activation of
coagulation cascade that occurs in response to different
diseases. It accounts for up to 1% of hospitalized patients
and may happen in a wide variety of severe medical con-
ditions, including sepsis, trauma, obstetrical complications,
transfusion and toxic reactions, rheumatologic illnesses,
vascular abnormalities and also in neoplasms [1].
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DOI 10.1007/s10585-010-9335-yThe association between neoplasms and DIC is well-
known and has been described in both solid and hemato-
logic malignancies. DIC has been reported to be present in
approximately 15–20% of patients with acute leukaemia
(up to 90% in acute promyelocytic leukaemia, APL) [2]
and in 7–15% of patients with metastatic solid tumours
[3–6]. The mechanisms leading to DIC in patients with
cancer are unclear [1, 7]. Experimental studies indicate that
the solid tumour and injured endothelial cells may release
mediators with a procoagulant activity (i.e., tissue factor
and cancer procoagulant) [8] or, alternatively, induce a
hypoﬁbrinolytic state mostly due to high levels of the
ﬁbrinolytic inhibitor PAI-1 [9]. Virtually all pathways that
contribute to the occurrence of DIC are driven by proin-
ﬂammatory cytokines such as tumour necrosis factor,
interleukin-1b, interleukin-6 and interleukin-8 [10, 11].
Patients with malignancy-driven DIC usually demon-
strate thrombocytopenia, hypoﬁbrinogenemia, and elevated
serum levels of D-dimers and ﬁbrinogen degradation
products [3, 12]. They may, however, be asymptomatic
despite demonstrable laboratory features of excess throm-
bin generation, which has been referred to as chronic or
low-grade DIC [7, 13]. Chronic systemic activation of
coagulation can, eventually, lead to exhaustion of platelets
and coagulation factors. Thus bleeding may be the ﬁrst
clinical symptom indicating the presence of DIC. Severe
bleeding episodes may also result from the activation of the
ﬁbrinolytic system which predominates in metastatic
prostate cancer, pancreatic adenocarcinoma or APL
[3, 4, 14, 15].
Very uncommonly, patients with rhabdomyosarcoma
(RMS) may present with clinical and/or laboratory features
of DIC. Such presentations were seen mainly in widespread
alveolar RMS metastatic to BM [16]. Only few reports on
RMS with DIC are available in the literature. Here we
describe two cases of widespread RMS in adolescents with
clinical presentation of severe haemorrhages resulting from
DIC. Both patients demonstrated also the laboratory fea-
tures of acute tumour lysis syndrome (ATLS) which,
together with DIC, were strongly suggestive for acute
hematologic malignancy and exceptionally rare in RMS
course [17].
Patients’ characteristics
Patient 1
A 14-year-old boy was admitted to the Department of
Paediatric Oncology, Medical University of Gdansk,
Poland in February 2007 suspected of acute leukaemia. For
2 weeks he had demonstrated severe back and abdominal
pains, fever, pallor, increasing skin diathesis and enlarged
lymph nodes of the neck. At admission the patient’s gen-
eral state was poor with signs of: anaemia, weakness,
cachexia and disseminated abundant haemorrhagic pete-
chiae and ecchymoses. Left retroauricular and bilateral
inguinal lymphadenopathy and slight hepato-splenomegaly
were found. During the 1st days of hospitalization he
developed new enlarged occipital lymph nodes and multi-
ple small (2–5 mm) nodules in the subcutaneous tissue of
chest, abdomen and back. He demonstrated dyspnoea due
to increasing volume of the bilateral pleural ﬂuid. Com-
puted Tomography (CT) additionally revealed huge medi-
astinal lymphatic masses and signiﬁcantly enlarged lymph
nodes in the spleen hilus and left kidney as well as ascites
and multiple metastatic nodules within peritoneum
(Fig. 1). Laboratory tests showed anaemia, thrombocyto-
penia and leucocytosis with left shift, ESR and C-reactive
protein values were slightly elevated. Laboratory signs of
ATLS (LDH[1,068 U/l, uric acid 9.3 mg/dl, phosphorus
5.2 mg/dl) and DIC (listed in Table 1) were present.
The repeated myelograms revealed massive dysery-
thropoietic features. Atypical cells constituted more than
50% of the BM cellularity and suggested strongly leukemic
blasts by morphology (Fig. 2). In ﬂow cytometry (FC),
however, the population of atypical cells did not display
antigens characteristic for the lymphoid and myeloid cell
lines. They were found CD45 negative (Fig. 3) and also
CD61, CD62, CD71 and CD235a negative. Normal popu-
lations of BM cells were found mostly within the CD45?
gate, apart from the erythroblasts, which were CD45 neg-
ative, but CD71 and CD235a positive in FC. Similar
immunophenotype of the metastatic cells was detected later
on in FC of the haemorrhagic pleural effusion. The atypical
cells displayed abnormal karyotype with partial trisomy of
chromosome 2 and partial tetrasomy of chromosome 6
(48,XY,?dic(2;6)(q21;p21),?6[6]). FISH examination of
BM did not detect the PML/RARA gene fusion.
Fig. 1 CT scan of the chest of the patient 1 revealing large amount of
free liquid in right pleural cavity with drainage and a pathological
nodule in subcutaneous tissue within the right anterior part of chest
wall
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123The surgical biopsy of the retroauricular lymph node
and two subcutaneous nodules was performed. Histopa-
thologically the sections demonstrated in part necrotic
neoplastic inﬁltrates made of small round and oval tumour
cells similar to those seen in the BM aspirate. The cells
were arranged in small lobules. Based on H-E staining the
initial diagnosis of lymphoma was made, which was
changed after the narrow introductory immunohistochem-
ical panel results into Ewing sarcoma. Because of the fast
neoplasm’s progression and increasing massive right
hemothorax resulting from uncontrollable DIC, the patient
was given life-saving chemotherapy (CHT) despite the lack
of deﬁnite histopathologic and cytologic diagnosis. The
patient received treatment effective in both malignant
non-Hodgkin’s lymphoma and Ewing sarcoma, including:
corticosteroids, vincristin, etoposide, adriamycin and
cyclophosphamide. Up to 2,000 ml of haemorrhagic ﬂuid a
day was drained from the right pleural cavity (Fig. 1). The
patient was also bleeding from postoperational scars,
injection spots and stomach. D-dimers increased up to
12,000 and Hb and PLT decreased to 7.3 g/dl and 15 g/l,
respectively. The patient required repeated blood products
transfusions and substitution of AT-III. Despite therapy,
massive hemothorax caused mediastinal displacement and
urgent right thoracotomy was performed disclosing huge
haematoma of the lower lobe of the right lung and neo-
plastic inﬁltration of the whole pleura. The biopsy from
pleural inﬁltration was taken and sent to referral histo-
pathologic centre. The patient was transferred to the
Emergency Unit and treated with mechanical ventilation
aimed to expand the right lung and possibly diminished
pleural bleeding.
After 3 days uniﬁed diagnosis of disseminated RMS of
most probably embryonal type with unknown primary site
was made. The patient was in extremely poor condition,
however we decided to introduce reduced doses of vin-
cristine, cyclophosphamide and actinomycin-D. After
2 days DIC parameters started to improve and bleeding and
skin diathesis gradually diminished. The lymphatic masses
started to shrink and the patient’ general state improved.
After 6 days the patient was extubated and then continued
CHT according to CWS-2002 protocol for childhood soft
tissue sarcomas. CT and myelogram examinations revealed
complete remission of the disease after two cycles of CHT.
Unfortunately, after the sixth one the patient demonstrated
severe neurologic abnormalities (chorea, ataxia, head-
aches). MRI of the brain showed multiple cortical and
subcortical metastatic foci with surrounding vasogenic
oedema. Despite aggressive therapy the patient died of
disease progression 3 months later.
Patient 2
A 14.5-year-old girl was admitted to our department in
January 2009 suspected of hematologic malignancy. For
2 weeks she had demonstrated poor general condition,
weakness, and severe headaches and pains of bones and of
the right inguinal area. She lost weight (10 kg) during the
previous 4 months. Abundant petechiae end ecchymoses
were present on the upper and lower limbs. Huge
(9 9 3.5 9 9 cm) tumour of the left parietal region and
slight hepato-splenomegaly were found in physical
Fig. 3 FC of the BM of patient 1 revealed the presence of a
population of CD45 negative cells (A), constituting more than 50% of
the BM cells (this corresponded to the result of the morphologic
examination of BM). These atypical cells were diagnosed as BM
metastases of a malignant nonhematopoietic tumour because they did
not display antigens characteristic for lymphoid or myeloid cell lines,
being CD61, 62, 71 and 235a negative. Normal BM cells were found
mostly within the CD45? gate (neutrophils—B, lymphocytes—C),
apart from the erythroblasts, which were CD45 negative, but also
CD71 and CD235a positive in FC
Fig. 2 BM smear of the patient 1 with extensive inﬁltration by a
homogeneous population of the primitive malignant small round blue
cells (haematoxylin and eosin stain, low-power view). These cell
were desmin positive and represented BM RMS metastases. Residual
hematopoietic cells are visible at the left upper quadrant of the picture
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123examination. In CT the tumour involved soft tissues and the
parietal bone. Laboratory tests revealed markedly decreased
platelet and haemoglobin levels and features suggestive for
DIC (Table 1) and ATLS (LDH 2,971 U/l, uric acid
10.4 mg/dl, phosphorus 5.3 mg/dl). In myelogram the
population of atypical cells accounting for over 50% of BM
was stated. By morphology they resembled leukemic blasts
(Fig. 4); in FC they were CD45 negative. The cytogenetic
analysis of atypical cells present in peripheral blood
displayed abnormal karyotype with multiple structural
and numerical abnormalities (90-94,XXXX,der(2)t(2;11)
(q35;q13),?del(5)(q11)x2,add(6)(q13)[2],-10,?der(12)t
(1;12)(q23;q13),-13,-13,-14,-16,?17,mar1,mar2,mar3,inc
[cp20]).
The tissue material from the ﬁrst neurosurgical biopsy
was not representative and devoid of neoplastic tissue, so
the repeated sampling was necessary. Before that the
condition of the patient dramatically worsened. She dem-
onstrated symptoms of increased intracranial pressure
conﬁrmed in eye fundus examination. Performed CT
images were irrelevant. The CNS symptoms resolved after
anti oedematous therapy and ﬂuids restriction. On the next
day severe dyspnoea with lowered alveolar sound over the
right lung occurred and the disseminated pulmonary
thromboembolism was stated. The patient received tissue
plasminogen activator in 48-h-infusion and subsequently,
low-molecular-weight heparins subcutaneously, with a
good clinical effect. Anticoagulative therapy resulted in
massive haemorrhage from the postoperational scar in the
parietal area and exacerbation of the skin diathesis,
requiring multiple blood transfusions. That is why the
second diagnostic biopsy of the parietal tumour had to be
postponed and instead, life-saving CHT was introduced.
Because no histopathologic diagnosis was available at that
moment and clinical symptoms suggested mostly Ewing
sarcoma, the patient received cycle of EURO-EWING 99
protocol, including vincristin, doxorubicin, ifosfamide and
etoposide. The doses were reduced because of poor general
state of the patient and ATLS features.
Finally, the histopathological diagnosis was established
upon the examination of trephine biopsy and then con-
ﬁrmed in the material obtained from the second neurosur-
gical parietal tumour biopsy performed 3 weeks after the
ﬁrst surgical attempt. The tissue material was scanty and in
part necrotic. The oval and spindled neoplastic cells were
dispersed in post chemotherapy regressively changed tis-
sue. The immunophenotype: desmin?, MyoD1?, Myf 4?,
S-100?, corresponded to the diagnosis of RMS of
unclassiﬁed subtype. The child was given CWS-2006
protocol for metastatic paediatric RMS and DIC signs
disappeared after the second cycle of CHT. Complete
remission has been stated since the third cycle until March
2010, when the relapse in the occipital region has been
stated.
Discussion
DIC is a rare feature of paediatric solid malignancies even
in metastatic phase. It has been reported in disseminated
neuroblastoma [26], nephroblastoma [27], infantile ﬁbro-
sarcoma [28] and multi-system Langerhans cell histiocy-
tosis [29]. However, most cases have been associated with
advanced RMS presenting with BM metastases [30].
Table 1 summarizes all cases of paediatric RMS presenting
with DIC published from 1978 till now, including both
Fig. 4 Bone marrow of the
patient 2 with big atypical
tumour cells with marked
cytoplasmic vacuolation
(May–Grunwald/Giemsa stain,
high power view), sharing some
similarities with lymphoblasts.
The cells were scattered,
sometimes gathered in small
clusters
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123cases presented herein. All these patients were reported to
fulﬁl the clinical and/or laboratory criteria of DIC. Most of
them were adolescents and males. In contrast to adult series
published previously, we have not stated a predominance
of alveolar subtype of RMS (RMA) in this group [30, 31].
This may result from the fact that RMA is less common
type of RMS in children and the most popular in adults.
Some authors have speculated that RMA disseminated to
BM is typically associated with hypercoagulability and/or
hyperﬁbrinolysis due to the presence of pathognomonic
translocation, t(2;13)(q35;q14) [30, 31].
The clinical utility of cytogenetic studies in the differ-
ential diagnostics of malignant small cell round tumours in
children has been reported and emphasized [32–34].
Accordingly, Ste ´phan et al. [32] have been able to diag-
nose disseminated RMA in a 15-year-old boy based on the
presence of this typical translocation [32]. However, other
than RMA types of childhood RMS lack any typical
cytogenetic abnormality. Our patients were diagnosed with
multiple but not prognostic chromosomal abnormalities
detected within the neoplastic cells. Therefore the proper
diagnoses of our patients (particularly of the patient 1)
were markedly delayed. The clinical symptoms of both
patients were suggestive for acute hematologic malignan-
cies, especially that the clinical and laboratory features of
DIC and ATLS were present. The presence of ATLS in
RMS is exceptionally rare [17] and there have been no
cases with both DIC and ATLS among childhood RMS
published to date.
By the nature of their morphology and biology, small
round cell tumours, particularly RMA may inﬁltrate the
marrow and can be misdiagnosed as acute leukemias. Also
clinical picture of disseminated RMS may sometimes
resemble acute hematologic malignancy, especially when
clinical and/or laboratory signs of DIC and ATLS occur
and no discernible primary lesion is found [34–36]. In our
patients serious problems to obtain representative diag-
nostic material occurred and both had to be biopsied once
more which was extremely risky because of DIC-associ-
ated-bleeding from incisional scars. There were several
conﬂicting initial diagnoses, including haematological and
non-haematological malignancies before, eventually; the
ﬁnal diagnoses of RMS were established after the consul-
tations of the specimens in three different histopathological
centres. It appears that FC immunophenotyping of BM
atypical cells is a valuable and available diagnostic tool in
such cases. By this method we were able to exclude the
diagnosis of leukemias and lymphoma by stating that the
metastatic cells were CD45 negative and did not display
any surface antigens characteristic for lymphoid or myeloid
cell lines. CD45 expression is regularly lower on leukemic
blasts than on normal lymphoid and myeloid cells, but
CD45 negative leukemias are extremely rare and the
atypical cells were CD235a negative, which excluded
erythroleukemia.
Unfortunately, we were not able to perform the CD56
phenotyping. Recently, the FC CD45- CD56? immuno-
proﬁle together with Myf4 transcript have been assigned to
RMS cells inﬁltrating BM [37]. The immunoproﬁle
CD45- CD56? alone is not enough to identify the RMS
cells as it is present in many types of nonhematopoietic
small round blue cell tumours, including neuroblastoma,
neuroendocrine and mesenchymal tumours [38].
The prognosis in RMS metastatic to BM is very poor
especially in cases complicated with DIC. Thus it is of
utmost importance to introduce early polychemotherapy
aimed at diminishing the malignancy-triggered procoagu-
lant activity [39] even if the deﬁnite histopathologic
diagnosis is inconclusive. In an inoperable situation, an
immediate beneﬁcial effect has been stated upon admin-
istration of multidrug CHT, even if a measurable antitumor
effect is not observed [40]. In most patients summarized in
Table 1 such life-saving, individual treatment contained
cytostatics acting in different phases of the malignant cell
proliferation cycle [41]. That is why we introduced CHT
immediately, despite inconclusive diagnosis and poor
patients’ condition with massive acute bleedings. Fortu-
nately both patients responded well to the treatment and
DIC symptoms signiﬁcantly diminished after the ﬁrst and
disappeared after the second cycle of CHT.
Once the treatment has been directed at the primary
illness, the additional therapy of DIC itself may be added.
In patients listed in Table 1 neither treatment of cancer nor
the supportive management of DIC was homogeneous.
Generally, the routine platelet replacement is not indicated
in acute DIC unless ongoing bleeding is present or invasive
procedures are planned [42]. In patient 1 massive haem-
orrhage from the pleura required as many as 57 units of
erythrocytes and 69 units of platelets transfusions. Patient 2
was transfused during haemorrhage from postoperational
scar, however she developed anti-platelet antibodies and
was not supplemented with platelets despite very low
levels. The role of high- or low-dose heparin therapy in
malignancy-associated DIC is still controversial, however
it is indicated in cases with obvious thromboembolic dis-
ease or where ﬁbrin deposition predominates [43, 44]. The
majority of patients listed in Table 1 did not receive hep-
arin treatment. In our material patient 2 needed immediate
anticoagulating for pulmonary thromboembolism, however
it resulted in massive hemorrhagic complications. In both
patients clinical and laboratory signs of DIC vanished
along with good response to CHT. Similarly, among the
patients presented in Table 1 good response to CHT was
associated with fast disappearance of the DIC symptoms.
Clin Exp Metastasis (2010) 27:399–407 405
123Conclusion
The clinical picture of a wide-spread RMS may resemble
acute hematologic malignancy and pose a big diagnostic
problem, especially when patients present with clinical
and/or laboratory signs of DIC and ATLS. The presence of
cells morphologically similar to lymphoblasts and/or my-
eloblasts in the BM, lacking hematopoietic makers, should
prompt the hematopathologist to consider possible diag-
nosis of RMS. Inclusion of desmin, MyoD1 and Myf4 to
the immunohistochemical panel is obligatory in such cases.
When the representative histopathological tumour speci-
mens are difﬁcult to obtain, the FC immunophenotyping of
BM metastases could help the standard morphological/
immunohistological diagnostic procedures and advance
the diagnosis. Recently, the ﬂow cytometric CD45-
CD56? immunophenotype together with Myf4 transcript
has been assigned to RMS cells inﬁltrating the BM.
Because of the extremely poor prognosis in children with
disseminated RMS complicated with DIC and ATLS,
proper polychemotherapy aimed at diminishing the
malignancy-triggered procoagulant activity should be ini-
tiated as soon as possible.
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